Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GB-NCS3
- Development stage
- Preclinical
- Lead developer
- GlycosBio
- Administration
- Oral
01
Overview
GB-NCS3 is a lipid-engineered nutraceutical candidate developed by GlycosBio for the management of sarcopenia. It utilizes the company's proprietary Activated Oil System technology, which is designed to enhance the bioavailability and delivery of specific nutritional components to support muscle mass and health. Unlike traditional pharmaceutical drugs that target specific molecular pathways, GB-NCS3 is categorized as a functional food or nutraceutical intended to address age-related muscle loss through optimized lipid delivery. It is currently in the clinical stage of development.
- Other names
- GB-NCS-3GB-NCS3GB-NCS 3
Beyond the preview
Go deeper on GB-NCS3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GB-NCS3.